Effective today, Merck KGaA, Darmstadt, Germany, will have non-exclusive global marketing and commercialization rights to Progyny's Early Embryo Viability Assessment Test, or Eeva® Test, while the former agreement had granted Merck KGaA, Darmstadt, Germany exclusive rights to commercialize the Eeva® Test in Europe and Canada, with the option to extend to selected countries. This renewed collaboration further builds upon the successful relationship between both leaders in fertility technologies initiated in 2010.
The innovative Eeva® Test brings insight and accuracy to the fertility clinic lab, arming embryologists with a non-invasive predictive test designed to aid in the assessment of embryos during an in vitro fertilization procedure. Based on landmark research conducted at Stanford University, the Eeva Test uses time-lapse imaging data to consistently and objectively access early embryo development milestones without disturbing the embryos during incubation.
This new agreement allows for extended distribution of the Eeva Test software. Further, this agreement allows for the Eeva Test to be sold as a software only platform opening up new possibilities for collaborations in the non-invasive embryo assessment field.